Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1995; 26:380-387
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iliceto, S
Right arrow Articles by Rizzon, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iliceto, S
Right arrow Articles by Rizzon, P

Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial

S Iliceto, D Scrutinio, P Bruzzi, G D'Ambrosio, L Boni, M Di Biase, G Biasco, PG Hugenholtz, and P Rizzon

Institute of Cardiology, University of Bari, Italy.

OBJECTIVES. This study was performed to evaluate the effects of L-carnitine administration on long-term left ventricular dilation in patients with acute anterior myocardial infarction. BACKGROUND. Carnitine is a physiologic compound that performs an essential role in myocardial energy production at the mitochondrial level. Myocardial carnitine deprivation occurs during ischemia, acute myocardial infarction and cardiac failure. Experimental studies have suggested that exogenous carnitine administration during these events has a beneficial effect on function. METHODS. The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial was a randomized, double-blind, placebo-controlled, multicenter trial in which 472 patients with a first acute myocardial infarction and high quality two-dimensional echocardiograms received either placebo (239 patients) or L-carnitine (233 patients) within 24 h of onset of chest pain. Placebo or L-carnitine was given at a dose of 9 g/day intravenously for the first 5 days and then 6 g/day orally for the next 12 months. Left ventricular volumes and ejection fraction were evaluated on admission, at discharge from hospital and at 3, 6 and 12 months after acute myocardial infarction. RESULTS. A significant attenuation of left ventricular dilation in the first year after acute myocardial infarction was observed in patients treated with L-carnitine compared with those receiving placebo. The percent increase in both end-diastolic and end-systolic volumes from admission to 3-, 6- and 12-month evaluation was significantly reduced in the L-carnitine group. No significant differences were observed in left ventricular ejection fraction changes over time in the two groups. Although not designed to demonstrate differences in clinical end points, the combined incidence of death and congestive heart failure after discharge was 14 (6%) in the L-carnitine treatment group versus 23 (9.6%) in the placebo group (p = NS). Incidence of ischemic events during follow-up was similar in the two groups of patients. CONCLUSIONS. L-Carnitine treatment initiated early after acute myocardial infarction and continued for 12 months can attenuate left ventricular dilation during the first year after an acute myocardial infarction, resulting in smaller left ventricular volumes at 3, 6 and 12 months after the emergent event.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
V. Soukoulis, J. B. Dihu, M. Sole, S. D. Anker, J. Cleland, G. C. Fonarow, M. Metra, E. Pasini, T. Strzelczyk, H. Taegtmeyer, et al.
Micronutrient deficiencies an unmet need in heart failure.
J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1660 - 1673.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. T. Turer, R. D. Stevens, J. R. Bain, M. J. Muehlbauer, J. van der Westhuizen, J. P. Mathew, D. A. Schwinn, D. D. Glower, C. B. Newgard, and M. V. Podgoreanu
Metabolomic Profiling Reveals Distinct Patterns of Myocardial Substrate Use in Humans With Coronary Artery Disease or Left Ventricular Dysfunction During Surgical Ischemia/Reperfusion
Circulation, April 7, 2009; 119(13): 1736 - 1746.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. Parang, B. Singh, and R. Arora
Metabolic Modulators for Chronic Cardiac Ischemia
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 217 - 223.
[Abstract] [PDF]


Home page
Physiol. Rev.Home page
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk
Myocardial Substrate Metabolism in the Normal and Failing Heart
Physiol Rev, July 1, 2005; 85(3): 1093 - 1129.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
J. J. Magner and D. Royston
Heart failure
Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
G. D. Lopaschuk and M. Marzilli
Mode of Action of Trimetazidine and Other New Metabolic Agents in the Treatment of Ischemic Heart Disease
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 91 - 96.
[PDF]


Home page
J Am Coll CardiolHome page
K. K. A. Witte, A. L. Clark, and J. G. F. Cleland
Chronic heart failure and micronutrients
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1765 - 1774.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Taniguchi, C. Wilson, C. A. Hunter, D. J. Pehowich, A. S. Clanachan, and G. D. Lopaschuk
Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1762 - H1769.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Nemoto, M. Aoki, C. Dehua, and Y. Imai
Effects of carnitine on cardiac function after cardioplegic ischemia in neonatal rabbit hearts
Ann. Thorac. Surg., January 1, 2001; 71(1): 254 - 259.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D Scrutinio, V Napoli, A Passantino, A Ricci, R Lagioia, and P Rizzon
Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome
Eur. Heart J., June 1, 2000; 21(11): 927 - 934.
[Abstract] [PDF]


Home page
Eur J Heart FailHome page
A. Gurlek, E. Tutar, E. Akcil, I. Dincer, C. Erol, P. A. Kocaturk, and D. Oral
The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy
Eur J Heart Fail, June 1, 2000; 2(2): 189 - 193.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Yokogawa, Y. Higashi, I. Tamai, M. Nomura, N. Hashimoto, H. Nikaido, J.-I. Hayakawa, K.-I. Miyamoto, and A. Tsuji
Decreased Tissue Distribution of L-Carnitine in Juvenile Visceral Steatosis Mice
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 224 - 230.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
V. A. Keller, B. Toporoff, R. M. Raziano, J. D. Pigott, and N. L. Mills
Carnitine supplementation improves myocardial function in hearts from ischemic diabetic and euglycemic rats
Ann. Thorac. Surg., November 1, 1998; 66(5): 1600 - 1603.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Repletion of L-Carnitine After MI May LimitLV Remodeling
Journal Watch Cardiology, October 1, 1995; 1995(1001): 8 - 8.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement